{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:55:29Z","timestamp":1786460129630,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This systematic review will assess the cost-effectiveness of clopidogrel in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Antiplatelet drugs, including clopidogrel, ticagrelor, prasugrel, and aspirin, are crucial in managing ACS, preventing ischemia, and, ultimately, death in PCI patients. Clopidogrel is the main treatment for those who have undergone PCI, used either alone or with aspirin. The incidence of ACS is rising globally, and is a major cause of premature death for millions. ACS management involves continuous medical therapy and costly procedures such as PCI, significantly straining health care resources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria:<\/jats:title>\n                    <jats:p>Studies will be eligible for inclusion if they report on the cost-effectiveness of clopidogrel in patients with ACS compared with other antiplatelet drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This systematic review will adhere to the JBI methodology for systematic reviews of economic evaluation evidence. A preliminary search was conducted of MEDLINE (PubMed) using MeSH terms. Two independent reviewers will screen records at the title\/abstract level, followed by full-text screening. Two reviewers will then assess methodological quality and extract data as per JBI guidelines. The JBI Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the included studies. The cost-effectiveness measures will be incremental cost, incremental cost per quality-adjusted life year gained, or incremental cost per disability-adjusted life year averted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used to appraise the certainty of economic evidence, such as using resources and expenditure, for incorporating the results into the decision-making process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Review registration:<\/jats:title>\n                    <jats:p>PROSPERO CRD42024504614<\/jats:p>\n                  <\/jats:sec>","DOI":"10.11124\/jbies-24-00390","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:01:12Z","timestamp":1747882872000},"page":"1824-1831","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review protocol"],"prefix":"10.11124","volume":"23","author":[{"given":"Saba","family":"Abidi","sequence":"first","affiliation":[{"name":"School of Allied Health Sciences and Management, Delhi Pharmaceutical Sciences and Research University, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shridhar","family":"Dwivedi","sequence":"additional","affiliation":[{"name":"National Heart Institute, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Sharma","sequence":"additional","affiliation":[{"name":"National Heart Institute, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushama","family":"Talegaonkar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4486-632X","authenticated-orcid":false,"given":"Denny","family":"John","sequence":"additional","affiliation":[{"name":"Faculty of Life and Allied Health Sciences, MS Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India"},{"name":"JBI Evidence-Based Indigenous Health India, MANT (Manbhum Ananda Ashram Nityananda Trust), Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"10","key":"R2-20250910","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4065\/84.10.917","article-title":"Acute coronary syndromes: diagnosis and management, part I","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"25","key":"R3-20250910","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global Burden of Cardiovascular Diseases and Risks Collaborators. Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"R4-20250910","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41569-023-00884-0","article-title":"Global epidemiology of acute coronary syndromes","volume":"20","author":"Timmis","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"R6-20250910","doi-asserted-by":"crossref","first-page":"ITC17","DOI":"10.7326\/AITC201908060","article-title":"Stable ischemic heart disease","volume":"171","author":"Katz","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"R7-20250910","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15420\/ecr.2016:34:2","article-title":"Antiplatelet therapy in acute coronary syndrome","volume":"12","author":"Layne","year":"2017","journal-title":"Eur Cardiol"},{"issue":"14","key":"R8-20250910","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"R9-20250910","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/ehjqcco\/qcv023","article-title":"Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention","volume":"2","author":"Wisl\u00f8ff","year":"2016","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R10-20250910","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1057\/s41599-021-00940-5","article-title":"Cost-effectiveness in health: consolidated research and contemporary challenges","volume":"8","author":"dos Santos Silva","year":"2021","journal-title":"Humanit Soc Sci Commun"},{"issue":"21","key":"R11-20250910","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"R12-20250910","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"31","key":"R13-20250910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15310","article-title":"Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no. 90): a systematic review and economic analysis","volume":"15","author":"Greenhalgh","year":"2011","journal-title":"Health Technol Assess"},{"issue":"4","key":"R14-20250910","doi-asserted-by":"crossref","first-page":"E438","DOI":"10.9778\/cmajo.20150056","article-title":"Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model","volume":"3","author":"Abdel-Qadir","year":"2015","journal-title":"CMAJ Open"},{"issue":"2","key":"R15-20250910","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jacasi.2022.12.007","article-title":"Cost-effectiveness of clopidogrel vs aspirin monotherapy after percutaneous coronary intervention: results from the HOST-EXAM study","volume":"3","author":"Hwang","year":"2023","journal-title":"JACC Asia"},{"issue":"1","key":"R16-20250910","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/CIRCOUTCOMES.113.000674","article-title":"Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China","volume":"7","author":"Wang","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"R17-20250910","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00392-013-0552-7","article-title":"Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany","volume":"102","author":"Theidel","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"R18-20250910","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CEOR.S51052","article-title":"Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada","volume":"6","author":"Grima","year":"2014","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"R19-20250910","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/ehjcvp\/pvac037","article-title":"Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome","volume":"9","author":"van den Broek","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"R20-20250910","first-page":"94","article-title":"Cost-effectiveness comparison between ticagrelor and clopidogrel in acute coronary syndrome in Iran","volume":"18","author":"Hashemi-Meshkini","year":"2023","journal-title":"J Tehran Heart Cent"},{"issue":"1","key":"R22-20250910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R23-20250910","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"R24-20250910","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/XEB.0000000000000152","article-title":"The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI)","volume":"17","author":"Munn","year":"2019","journal-title":"Int J Evid Based Healthc"},{"key":"R25-20250910","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"R26-20250910","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"R27-20250910","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R28-20250910","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"R30-20250910","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jclinepi.2012.04.012","article-title":"GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence","volume":"66","author":"Brunetti","year":"2013","journal-title":"J Clin Epidemiol"}],"container-title":["JBI Evidence Synthesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-24-00390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:32:54Z","timestamp":1786451574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-24-00390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.11124\/jbies-24-00390","relation":{},"ISSN":["2689-8381"],"issn-type":[{"value":"2689-8381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}